Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
Relief Therapeutics (RLFTY) has announced its upcoming 2025 Annual General Meeting (AGM) scheduled for June 12, 2025 at 10:00 a.m. CEST in Geneva, Switzerland. The AGM agenda includes standard items such as approval of the 2024 annual report and financial statements, earnings appropriation, board and executive committee discharge, and re-election of board members and chairman.
Additional agenda items cover re-election of nomination and compensation committee members, approval of maximum compensation for board and executive committee, a consultative vote on the 2024 compensation report, and re-election of independent voting rights representative and auditors. Formal convocation notice will be mailed to registered shareholders on May 21, 2025.
Relief Therapeutics (RLFTY) ha annunciato la sua prossima Assemblea Generale Annuale (AGM) 2025, prevista per il 12 giugno 2025 alle ore 10:00 CEST a Ginevra, Svizzera. L'ordine del giorno dell'AGM comprende punti standard come l'approvazione del bilancio e del rapporto annuale 2024, la destinazione degli utili, la liberatoria per il consiglio e il comitato esecutivo, e la rielezione dei membri del consiglio e del presidente.
Ulteriori punti all'ordine del giorno includono la rielezione dei membri del comitato di nomina e compensi, l'approvazione del compenso massimo per il consiglio e il comitato esecutivo, una votazione consultiva sul rapporto compensi 2024, e la rielezione del rappresentante indipendente dei diritti di voto e dei revisori. La convocazione formale sarà inviata per posta agli azionisti registrati il 21 maggio 2025.
Relief Therapeutics (RLFTY) ha anunciado su próxima Junta General Anual (AGM) 2025, programada para el 12 de junio de 2025 a las 10:00 a.m. CEST en Ginebra, Suiza. La agenda de la AGM incluye puntos estándar como la aprobación del informe anual y estados financieros de 2024, la asignación de ganancias, la aprobación de la gestión del consejo y comité ejecutivo, y la reelección de los miembros del consejo y del presidente.
Otros puntos en la agenda abarcan la reelección de los miembros del comité de nominación y compensación, la aprobación de la compensación máxima para el consejo y el comité ejecutivo, una votación consultiva sobre el informe de compensación 2024, y la reelección del representante independiente de derechos de voto y de los auditores. La convocatoria formal será enviada por correo a los accionistas registrados el 21 de mayo de 2025.
Relief Therapeutics (RLFTY)는 2025년 연례 주주총회(AGM)가 2025년 6월 12일 오전 10시 CEST에 스위스 제네바에서 개최될 예정임을 발표했습니다. AGM 의제에는 2024년 연례 보고서 및 재무제표 승인, 수익 배분, 이사회 및 집행위원회 면책, 이사회 구성원 및 의장 재선거 등 표준 항목이 포함됩니다.
추가 의제로는 지명 및 보상 위원회 구성원 재선거, 이사회 및 집행위원회 최대 보상 승인, 2024년 보상 보고서에 대한 자문 투표, 독립 의결권 대표 및 감사인 재선거가 포함됩니다. 정식 소집 통지서는 2025년 5월 21일 등록 주주에게 우편으로 발송될 예정입니다.
Relief Therapeutics (RLFTY) a annoncé sa prochaine Assemblée Générale Annuelle (AGM) 2025, prévue le 12 juin 2025 à 10h00 CEST à Genève, Suisse. L'ordre du jour de l'AGM comprend des points habituels tels que l'approbation du rapport annuel et des états financiers 2024, l'affectation des résultats, la décharge du conseil d'administration et du comité exécutif, ainsi que la réélection des membres du conseil et du président.
Les points supplémentaires à l'ordre du jour incluent la réélection des membres des comités de nomination et de rémunération, l'approbation de la rémunération maximale pour le conseil et le comité exécutif, un vote consultatif sur le rapport de rémunération 2024, ainsi que la réélection du représentant indépendant des droits de vote et des auditeurs. La convocation officielle sera envoyée par courrier aux actionnaires enregistrés le 21 mai 2025.
Relief Therapeutics (RLFTY) hat seine bevorstehende Jahreshauptversammlung (AGM) 2025 angekündigt, die für den 12. Juni 2025 um 10:00 Uhr MESZ in Genf, Schweiz, geplant ist. Die Tagesordnung der AGM umfasst Standardpunkte wie die Genehmigung des Jahresberichts und der Jahresabschlüsse 2024, die Gewinnverwendung, Entlastung des Vorstands und des Exekutivausschusses sowie die Wiederwahl der Vorstandsmitglieder und des Vorsitzenden.
Weitere Tagesordnungspunkte sind die Wiederwahl der Mitglieder des Nominierungs- und Vergütungsausschusses, die Genehmigung der maximalen Vergütung für Vorstand und Exekutivausschuss, eine beratende Abstimmung über den Vergütungsbericht 2024 sowie die Wiederwahl des unabhängigen Stimmrechtsvertreters und der Wirtschaftsprüfer. Die formelle Einladung wird am 21. Mai 2025 an die registrierten Aktionäre versandt.
- None.
- None.
GENEVA, SWITZERLAND / ACCESS Newswire / May 15, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published the agenda for its 2025 Annual General Meeting (AGM) of shareholders, to be held on June 12, 2025, at 10:00 a.m. CEST in Geneva, Switzerland.
The agenda includes approval of the 2024 annual report and financial statements, appropriation of available earnings, discharge of the board of directors and executive committee, re-election of the members of the board of directors and its chairman, re-election of the members of the nomination and compensation committee, and approval of the maximum compensation amounts for the board of directors and executive committee. Also included are a consultative vote on the 2024 compensation report and the re-election of the independent voting rights representative and auditors.
The formal notice of convocation of the AGM, including information regarding attendance in person or by proxy, notification and registration requirements, and ancillary documents relevant to the meeting, will be mailed to registered shareholders on May 21, 2025. The full agenda is available on the Relief website .
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
When is Relief Therapeutics (RLFTY) 2025 Annual General Meeting?
What are the key agenda items for Relief Therapeutics' 2025 AGM?
When will RLFTY shareholders receive the formal AGM notice?
What voting matters will be presented at Relief Therapeutics' 2025 AGM?
